Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
McKesson
Mallinckrodt
Moodys
Boehringer Ingelheim

Last Updated: June 26, 2022

CLINICAL TRIALS PROFILE FOR INSULIN SUSP ISOPHANE PURIFIED PORK


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Insulin Susp Isophane Purified Pork

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00658099 ↗ Observational Study of Type 2 Diabetes Patients Failing on Oral Anti-diabetic Agents Initiated on Levemir® or Insulatard® Completed Novo Nordisk A/S 2007-11-01 This trial is conducted in Europe. The aim of this observational study is to evaluate the change in weight in type 2 diabetes patients using Levemir® or Insulatard® under normal clinical practice conditions.
NCT00665808 ↗ Observational Study on Treatment Satisfaction of Levemir® Versus Protaphane® During "Real-life" Usage in Germany Completed Novo Nordisk A/S 2007-10-01 This NON INTERVENTIONAL OBSERVATIONAL STUDY is conducted in Europe. The purpose of this NON INTERVENTIONAL OBSERVATIONAL STUDY is to primarily investigate treatment satisfaction when using Levemir® versus Protaphane® in combination with OADs in daily settings.
NCT01122979 ↗ Evaluation of the Safety and Efficacy of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) Use in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure. Completed Sanofi Phase 4 2010-07-01 Primary Objective: >To obtain an estimation for both treatment groups of the proportion of patients that reach the target of HbA1c <= 7% without confirmed nocturnal hypoglycaemia in each treatment group. Secondary Objectives: - Glycemic control, measured by HbA1c and FPG (fasting plasma glucose) at baseline and after each period of treatment. - Incidence of confirmed symptomatic and nocturnal hypoglycemia. - Incidence of confirmed severe hypoglycemia (< 36mg/dL or need of help to recover). >Weight variation for each period of treatment. - Creatinine clearance at baseline and after each period of treatment. - Overall safety: Incidence of adverse events.
NCT01680185 ↗ Sensor-Augmented Insulin-Pump Therapy in New-onset Diabetes After Transplantation Completed Medical University of Vienna Phase 3 2012-08-01 The SAPT-NODAT study will test the hypotheses that intensive subcutaneous insulin treatment with short acting insulin, applied continuously through an insulin pump, (i) improves glycemic control, (ii) reduces the prevalence of NODAT and prediabetes, and (iii) offers further β-cell protection, in comparison to the standard of care control group, and the basal insulin treatment group. In the SAPT-NODAT study, we will employ sensor-augmented insulin-pump technology, which performs like a semi-closed loop to prevent hypoglycemic events. Patients in the SAPT-NODAT study will be followed through 24 months post-transplantation.
NCT01790438 ↗ A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes Completed Eli Lilly and Company Phase 3 2013-03-01 The purpose of this study is to compare LY2605541 and human insulin isophane suspension (NPH) using the following measures for participants treated for up to 26 weeks: - Change in participants' overall blood sugar control - The rate of night time low blood sugar episodes - The number of participants that reach blood sugar targets without low night time blood sugar episodes - The total number of low blood sugar episodes reported
NCT01963728 ↗ Comparison of Insulin Therapy in Treating Post-Transplant Diabetes Terminated Inova Health Care Services Phase 4 2014-05-01 To determine if the use of insulin isophane results in improved control of blood sugars compared to the use of insulin glargine in new onset diabetes after kidney, lung, or heart transplantation (NODAT).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Insulin Susp Isophane Purified Pork

Condition Name

Condition Name for Insulin Susp Isophane Purified Pork
Intervention Trials
Diabetes Mellitus, Type 2 4
Diabetes Mellitus 3
Diabetes 2
Hyperglycemia 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Insulin Susp Isophane Purified Pork
Intervention Trials
Diabetes Mellitus 7
Diabetes Mellitus, Type 2 4
Hyperglycemia 2
Renal Insufficiency 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Insulin Susp Isophane Purified Pork

Trials by Country

Trials by Country for Insulin Susp Isophane Purified Pork
Location Trials
United States 16
Germany 4
Canada 4
Mexico 1
Spain 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Insulin Susp Isophane Purified Pork
Location Trials
Virginia 1
Washington 1
Tennessee 1
South Carolina 1
Pennsylvania 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Insulin Susp Isophane Purified Pork

Clinical Trial Phase

Clinical Trial Phase for Insulin Susp Isophane Purified Pork
Clinical Trial Phase Trials
Phase 4 2
Phase 3 3
Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Insulin Susp Isophane Purified Pork
Clinical Trial Phase Trials
Completed 8
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Insulin Susp Isophane Purified Pork

Sponsor Name

Sponsor Name for Insulin Susp Isophane Purified Pork
Sponsor Trials
Medical University of Vienna 2
Profil Institut für Stoffwechselforschung GmbH 2
Julphar Gulf Pharmaceutical Industries 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Insulin Susp Isophane Purified Pork
Sponsor Trials
Industry 8
Other 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Colorcon
Boehringer Ingelheim
Harvard Business School
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.